Square Pharmaceuticals PlcDSEBD: SQURPHARMA

SQURPHARMA: Net profit up 13% to Tk. 12.70B; EPS and NAV per share both increased year-over-year

· Issued by Square Pharmaceuticals Plc

Group net profit rose 13% year-over-year to Tk. 12.70 billion on 6.1% higher revenue, with EPS up to Tk. 14.32. Net operating cash flow per share declined due to absence of prior year one-offs.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Square Pharmaceuticals

All Square Pharmaceuticals news releases